Abstract
Background and Objectives
Glycopyrronium is a once-daily long-acting muscarinic antagonist for the maintenance treatment of patients with chronic obstructive pulmonary disease. This study assessed the pharmacokinetics of inhaled glycopyrronium 50 µg once-daily for 14 days in healthy Chinese subjects.
Methods
In this open-label study, 12 Chinese healthy subjects (six males and six females; mean age 23.1 years [range 18–26 years]) were enrolled and completed the study. Glycopyrronium in plasma was determined using validated liquid chromatography–mass spectrometry method with a lower limit of quantification of 1.5 pg/mL. Plasma pharmacokinetic parameters were determined on Day 1 after first dose and on Day 14 (steady state) after last dose using non-compartmental analysis. Trough pharmacokinetic samples (Days 5, 7, 10 and 12) were collected. Safety was also assessed.
Results
Glycopyrronium was rapidly absorbed into the systemic circulation after inhalation and its plasma concentrations decreased rapidly thereafter. Median time to reach maximum concentration (T max) was reached within 5 min after inhalation on both Days 1 and 14. Accumulation in the systemic exposure to glycopyrronium was observed from the time of first dose administration on Day 1 up to Day 14 and the observed accumulation ratio (R acc) values of area under the plasma drug concentration–time curve [AUC] from time 0 to 24 h post-dose (AUC0–24h) and maximum plasma drug concentration (C max) (Day 14/Day 1) were 2.77 and 1.59, respectively. The elimination half-life (T 1/2) was not reported. Mean effective half-life (T 1/2,acc) was 37.7 h. Pharmacokinetic steady state was reached after 5 days of daily dosing. One subject experienced dry mouth; otherwise glycopyrronium was well tolerated.
Conclusions
Comparison of systemic exposure to glycopyrronium in Chinese versus the non-Chinese population did not indicate clinically relevant ethnic differences. Multiple inhaled doses of glycopyrronium were safe and well tolerated.
Similar content being viewed by others
References
GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015.
WHO. World health statistics. 2008. http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf Accessed 8 Apr 2015.
Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–60.
Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987–2015.
Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess. 2013;2:11–6.
SMPC. Novartis Europharm Ltd. Seebri® Breezhaler® (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf.
Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–53.
D’Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–14.
Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis. 2015;10:57–68.
Sechaud R, Renard D, Zhang-Auberson L, Motte Sde L, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118–28.
Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76(6):868–79.
Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771–9.
Drollmann A, Brown M, Sechaud R, Perry S, Hara H, Jones I, et al. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(5):369–80.
SFDA. State Food and Drug Administration, P.R.China, Guideline No. [H] GCL 1–2. Technical Guideline of Clinical Pharmacokinetics Research on Chemical Drug (in Chinese). 2005.
Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763–6.
Drollmann A, Sechaud R, Pal P, Hara H, Uziel-Fusi S, Winkle P. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study. Int J Clin Pharmacol Ther. 2014;52(9):739–45.
Acknowledgments
The authors thank the subjects and the staff at the participating clinical center. The authors also thank Vivek Khanna (professional medical writer; Novartis) for assistance in the preparation of this paper. Writing support was funded by Novartis Pharma AG, Basel, Switzerland. All authors participated in the development and writing of the manuscript and take full responsibility for the content of the article. All authors approved the final version that was submitted.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The study was supported and funded by Novartis Pharma AG, Basel, Switzerland. Writing support was funded by Novartis Pharma AG, Basel, Switzerland.
Conflict of interest
All authors have completed the Conflict of Interest Disclosure form and declare: RS, SM, HCT, HH, XT, RZ and SR are employees of Novartis. JH has no conflict of interest to declare.
Ethical approval
All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments), and the Ethical Committee or institutional review board which approved the study.
Informed consent
Written informed consent was obtained from patients, parents or care givers.
Rights and permissions
About this article
Cite this article
Sechaud, R., Machineni, S., Tillmann, HC. et al. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects. Eur J Drug Metab Pharmacokinet 41, 723–731 (2016). https://doi.org/10.1007/s13318-015-0300-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-015-0300-7